Premenstural syndrome. Unspecified behavioural syndromes associated with physiological disturbances and physical factors
Conditions
Interventions
Intervention 1: Placebo capsules, 1000 mg, 2 times a day, orally for 3 months. Intervention 2: Perforun Capsules, 240 mg, 2 times a day, orally for 3 months. Intervention 3: Fatty acid capsules three
Treatment - Drugs
Placebo capsules, 1000 mg, 2 times a day, orally for 3 months
Perforun Capsules, 240 mg, 2 times a day, orally for 3 months
Fatty acid capsules three thousand milligrams, twice daily for 3 months, orally
Sponsors
Tehran University of Medical Sciences
Eligibility
Sex/Gender
Female
Age
18 Years to 35 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: Regular menstrual cycles 24-35 days, 18-35 years of age and unmarried, non-psychotic mental illness, lack of physical illnesses including endocrine diseases known as non-hormonal drugs, anticoagulant, antidepressants, supplements and herbal medicine, not taking any medication for the treatment of premenstrual syndrome, No alcohol or drugs, sensitivity to the sun and sea food, relatives who died in the last 3 months, surgery in the last 3 months. Exclusion criteria: any disease endocrine disease during the study, having severe premenstrual syndrome, married during the study, Unwillingness to continue the study, If complications or allergic to a drug or other drug use, stop taking the medication for a week in regular cycles and irregular drug consumption in the second and third cycles for two days.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Reduction in physical symptoms (headache, breast swelling and tenderness, back pain, abdominal pain, muscle pain, weight gain, swelling of extremities, nausea, diarrhea or constipation). Timepoint: One month, two months, three months after intervention. Method of measurement: Questionnaire.;Reduction in behavioral symptoms (fatigue, lack of energy, insomnia, difficulty concentrating, increased appetite). Timepoint: One month, two months, three months after intervention. Method of measurement: Questionnaire.;Reduction in mood symptoms (irritability and restlessness, anxiety and impatience, anger, depression and sadness, crying for no reason, feeling alone). Timepoint: One month, two months, three months after intervention. Method of measurement: Questionnaire. | — |
Secondary
| Measure | Time frame |
|---|---|
| Side effects of drugs. Timepoint: Three months after the intervention. Method of measurement: Questionnaire. | — |
Countries
Iran (Islamic Republic of)
Outcome results
None listed